FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - February 11, 2026 104 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CEPHEUS study Source RELATED ARTICLESMORE FROM AUTHOR Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma MOST POPULAR FDA Expands Indications for Lutetium Lu 177 Vipivotide Tetraxetan to Include... April 25, 2025 Sacituzumab Govitecan Approved for Metastatic Triple-Negative Breast Cancer May 28, 2020 EMA Recommends Granting a Conditional Marketing Authorisation for Pemigatinib February 1, 2021 Triple Negative Breast Cancer May Not Be Categorized As ‘Breast’ Cancer... February 4, 2020 Load more HOT NEWS Reunión anual de la American Society of Clinical Oncology de 2022:... Adjuvant Pembrolizumab Improves Overall Survival Among Patients with Clear-Cell Renal Cell... Encouraging Single-Agent Antitumour Activity of Divarasib Across KRAS G12C-positive Tumours Analysis Shows Women with High Breast Cancer Recurrence Scores Benefit from...
